ROHTO PHARMACEUTICAL CO.,LTD.

Transcripts Rohto Pharmaceutical Co.,Ltd.

Equities

4527

JP3982400008

Delayed Japan Exchange Other stock markets 03:01:58 10/05/2024 BST			5-day change	1st Jan Change
3,225 ^JPY	+2.51%		+5.22%	+13.40%

04-04	Rohto Pharmaceutical Eyes MGO on Singapore's Eu Yan Sang International for 88 Billion Yen	MT
04-04	Rohto Pharmaceutical, Mitsui & Co. to Acquire Singapore-Based Eu Yan Sang -- Update	DJ

Transcripts

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Rohto Pharmaceutical Co.,Ltd. Provides Earnings Guidance for the Fiscal Year Ending March 31, 2023	20/05/22	CI
Rohto Pharmaceutical Co.,Ltd. Provides Earnings Guidance for the Fiscal Year Ending March 31, 2022	17/02/22	CI
Rohto Pharmaceutical Co.,Ltd. Provides Earnings Guidance for the Fiscal Year Ending March 31, 2022	18/11/21	CI
Rohto Pharmaceutical Co.,Ltd. Provides Consolidated Earnings Guidance for the Fiscal Year Ending March 31, 2022	18/08/21	CI
Rohto Pharmaceutical Co., Ltd. Provides Earnings Guidance for the Fiscal Year Ending March 31, 2022	21/05/21	CI
Rohto Pharmaceutical Co., Ltd. Provides Consolidated Earnings Guidance for the Year Ending March 31, 2021	17/02/21	CI
Rohto Pharmaceutical Co., Ltd. Provides Earnings Guidance for the Fiscal Year Ending March 31, 2021	18/11/20	CI
Rohto Pharmaceutical Co., Ltd. Provides Consolidated Earnings Guidance for the Year Ending March 31, 2021	10/08/20	CI
Rohto Pharmaceutical Co., Ltd. Provides Consolidated Earnings Guidance for the Year Ending March 31, 2021	26/05/20	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

+39.41% on our US portfolio vs. 25.67% on the S&P 500 net Total Return

Replicate our performance

fermer